Evidence map›Paper›PMID 36106144›Full record

ReviewEuropean urology open science2022

Oncological Follow-up Strategies for Testicular Germ Cell Tumours: A Narrative Review.

Ernest Kaufmann, Luca Antonelli, Peter Albers, Clint Cary, Silke Gillessen Sommer, Axel Heidenreich, Christoph Oing, Jan Oldenburg, Phillip Martin Pierorazio, Andrew J Stephenson and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European urology open science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ernest KaufmannUniversity of Zurich, Zurich, Switzerland.
Luca AntonelliDepartment of Urology, Luzerner Kantonssspital, Lucerne, Switzerland.
Peter AlbersDepartment of Urology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
Clint CaryDepartment of Urology, Indiana University School of Medicine, Indianapolis, IN, USA.
Silke Gillessen SommerOncology Institute of Southern Switzerland, Bellinzona, Switzerland.
Axel HeidenreichDepartment of Urology, University Hospital Cologne, Cologne, Germany.
Christoph OingSir Bobby Robson Cancer Trials Research Centre, Department of Cancer Services, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Jan OldenburgDepartment of Oncology, Akershus University Hospital and Medical Faculty of University of Oslo, Oslo, Norway.
Phillip Martin PierorazioThe James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew J StephensonDepartment of Urology, Rush University Medical Group, Chicago, IL, USA.
Christian Daniel FankhauserUniversity of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context: The aim of this review is to describe the proportion of testicular germ cell tumours (tGCTs) with recurrence, and the timing and anatomical sites of relapse across different disease stages and after different treatment options. We summarise published follow-up protocols and discuss current and future developments to personalise follow-up for patients with tGCT. Evidence acquisition: A systematic literature search was conducted and current guidelines and selected institutional follow-up protocols were reviewed. Evidence synthesis: Of 302 publications, we screened 68 full texts and included 29 studies; 22 of these were retrospective and seven were prospective in nature, contributing data for 20 570 patients. The number of patients included per study ranged from 119 to 2483. We compared the guideline follow-up protocols of the European Society for Medical Oncology, European Association of Urology, National Comprehensive Cancer Network, and American Urological Association, as well as institutional follow-up protocols. The protocols differed in terms of the number, time points, and type of follow-up investigations. Conclusions: Future research should assess how tGCT can be followed to ensure high adherence, define the role of miR-371a-3p microRNA during follow-up, and develop follow-up protocols after curative treatment in the metastatic setting. Patient summary: In this review of follow-up protocols for men with testis cancer, we observed different recommendations and discuss future research areas to improve follow-up for these patients.

Indexed as

Cross-sectional imagingFollow-upGerm cell tumourGuidelinesRelapseSerum markersTestis

Identifiers

PMID36106144
PMCPMC9465095

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.